SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): November 2, 2007 (October
30, 2007)
CHEMBIO
DIAGNOSTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
On
November 2, 2007, the Company issued the press release titled “Chembio
Diagnostics Receives CLIA Waiver for HIV Barrel Test” included herein as Exhibit
99.1.
On
November 2, 2007, the Company issued the press release titled “Chembio Reports
Third Quarter Results” included herein as Exhibit 99.2.
On
October 31, 2007, the Company issued the press release titled “Chembio to Host
Conference Call to Discuss Third Quarter Financial Results for 2007” included
herein as Exhibit 99.3.
On
October 30, 2007, the Company issued the press release titled “Chembio
Diagnostics, Inc. to Present at Acumen BioFin Rodman and Renshaw 9th Annual
Healthcare
Conference” included herein as Exhibit 99.4.
On
November 5, 2007, certain officers of the Company intend
to deliver an investor presentation that will include the
slides attached hereto as Exhibit 99.5 to this Current Report on Form
8-K. The Company undertakes no obligation to update, supplement or
amend the materials attached as Exhibit 99.5.
Attached
as Exhibit 99.6 is a presentation prepared for preferred
stockholders.
ITEM
9.01. Financial Statements and Exhibits
Exhibits.
|
99.1
|
Press
Release titled “Chembio
Diagnostics Receives CLIA Waiver for HIV Barrel
Test” issued
November 2, 2007.
|
|
99.2
|
Press
Release titled “Chembio
Reports Third Quarter Results” issued November
2,
2007.
|
|
99.3
|
Press
Release titled “Chembio
to Host Conference Call to Discuss Third Quarter
Financial Results for 2007” issued October
31,
2007.
|
|
99.4
|
Press
Release titled “Chembio
Diagnostics, Inc. to Present at Acumen BioFin
Rodman and Renshaw 9th
Annual
Healthcare Conference”
issued October 30, 2007.
|
In
accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K shall not be deemed “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing. This Current Report on Form
8-K does not constitute a determination of whether any information included
herein is material.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: November
2,
2007 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A.
Siebert
Lawrence
A. Siebert
Chief
Executive Officer